Tumor suppressor function of RUNX3 in breast cancer

Journal of Cellular Biochemistry

Volumn 113, Issue 5, 2012, Pages 1470-1477

  Chen, Lin Feng ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

BREAST CANCER; ESTROGEN RECEPTOR; INACTIVATION; RUNX3; TUMOR SUPPRESSOR

Indexed keywords

TRANSCRIPTION FACTOR RUNX3;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CYTOPLASM; GENE DELETION; GENE INACTIVATION; HUMAN; INTRADUCTAL CARCINOMA; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RUNX3 GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BREAST NEOPLASMS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 84859038293     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24074     Document Type: Article

References (75)

1. Adya N, Stacy T, Speck NA, Liu PP,. 1998. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol 18: 7432-7443. (Pubitemid 28533062)
2. Bae SC, Lee YH,. 2006. Phosphorylation, acetylation and ubiquitination: The molecular basis of RUNX regulation. Gene 366: 58-66. (Pubitemid 43199594)
3. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG,. 1997. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med (Berl) 75: 429-439. (Pubitemid 27297013)
4. Berry NB, Fan M, Nephew KP,. 2008. Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol Endocrinol 22: 1535-1551. (Pubitemid 351920389)
5. Boras-Granic K, Wysolmerski JJ,. 2008. Wnt signaling in breast organogenesis. Organogenesis 4: 116-122. (Pubitemid 351881309)
6. Brooks J, Cairns P, Zeleniuch-Jacquotte A,. 2009. Promoter methylation and the detection of breast cancer. Cancer Causes Control 20: 1539-1550.
7. Chen W, Salto-Tellez M, Palanisamy N, Ganesan K, Hou Q, Tan LK, Sii LH, Ito K, Tan B, Wu J, Tay A, Tan KC, Ang E, Tan BK, Tan PH, Ito Y, Tan P,. 2007. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes, Chromosomes Cancer 46: 288-301. (Pubitemid 46155323)
8. Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang TH,. 2008. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res 68: 1786-1796. (Pubitemid 351416564)
9. Cheskis BJ, Greger JG, Nagpal S, Freedman LP,. 2007. Signaling by estrogens. J Cell Physiol 213: 610-617. (Pubitemid 350058252)
10. Chi XZ, Kim J, Lee YH, Lee JW, Lee KS, Wee H, Kim WJ, Park WY, Oh BC, Stein GS, Ito Y, van Wijnen AJ, Bae SC,. 2009. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res 69: 8111-8119.
11. Chuang LS, Ito Y,. 2010. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29: 2605-2615.
12. Cohen MM, Jr., 2003. TGF beta/Smad signaling system and its pathologic correlates. Am J Med Genet A 116A: 1-10. (Pubitemid 36008061)
13. Drabsch Y, ten Dijke P,. 2011. TGF-beta signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia 16: 97-108.
14. Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, Cavailles V,. 2007. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 67: 5513-5521. (Pubitemid 46997293)
15. Fabbro M, Henderson BR,. 2003. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 282: 59-69. (Pubitemid 36259901)
16. Fan M, Nakshatri H, Nephew KP,. 2004. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 18: 2603-2615. (Pubitemid 39482052)
17. Fan M, Park A, Nephew KP,. 2005. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol 19: 2901-2914. (Pubitemid 41697710)
18. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M,. 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527. (Pubitemid 351655218)
19. Fujii S, Ito K, Ito Y, Ochiai A,. 2008. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332.
20. Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan YL, Du R, Zheng GR, Xiong YM, Xu HL, Fan DM,. 2010. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp Cell Res 316: 149-157.
21. Goh YM, Cinghu S, Hong ET, Lee YS, Kim JH, Jang JW, Li YH, Chi XZ, Lee KS, Wee H, Ito Y, Oh BC, Bae SC,. 2010. Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm. J Biol Chem 285: 10122-10129.
22. Guo WH, Weng LQ, Ito K, Chen LF, Nakanishi H, Tatematsu M, Ito Y,. 2002. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene 21: 8351-8355. (Pubitemid 35477876)
23. Guo S, Liu M, Gonzalez-Perez RR,. 2011. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 1815: 197-213.
24. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D, Salto-Tellez M, Ito K, Ito Y, Chen LF,. 2011. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 31: 527-534.
25. Hwang KT, Han W, Bae JY, Hwang SE, Shin HJ, Lee JE, Kim SW, Min HJ, Noh DY,. 2007. Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer. J Korean Med Sci 22 (Suppl): S24-S31.
26. Inoue K, Ozaki S, Shiga T, Ito K, Masuda T, Okado N, Iseda T, Kawaguchi S, Ogawa M, Bae SC, Yamashita N, Itohara S, Kudo N, Ito Y,. 2002. Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat Neurosci 5: 946-954.
27. Ito Y,. 2004. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 23: 4198-4208. (Pubitemid 38765135)
28. Ito K,. 2011. RUNX3 in oncogenic and anti-oncogenic signaling in gastrointestinal cancers. J Cell Biochem 112: 1243-1249.
29. Ito Y, Miyazono K,. 2003. RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 13: 43-47. (Pubitemid 36143926)
30. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG, Ito Y,. 2005. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750. (Pubitemid 41297249)
31. Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, Fukamachi H, Ito Y,. 2008. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14: 226-237.
32. Jemal A, Siegel R, Xu J, Ward E,. 2010. Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
33. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. 2011. Global cancer statistics. CA Cancer J Clin 61: 69-90.
34. Jiang Y, Tong D, Lou G, Zhang Y, Geng J,. 2008. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology 75: 244-251. (Pubitemid 351918429)
35. Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, Kim WJ, Lee KY, Bae SC,. 2004. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 279: 29409-29417. (Pubitemid 38915820)
36. Jones PA, Baylin SB,. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428. (Pubitemid 34587077)
37. Jones PA, Baylin SB,. 2007. The epigenomics of cancer. Cell 128: 683-692. (Pubitemid 46273572)
38. Jovanovic J, Ronneberg JA, Tost J, Kristensen V,. 2010. The epigenetics of breast cancer. Mol Oncol 4: 242-254.
39. Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, Robertson KD, Bang YJ,. 2007. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J Mol Med 85: 1137-1148. (Pubitemid 47476731)
40. Kanno Y, Kanno T, Sakakura C, Bae SC, Ito Y,. 1998. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol 18: 4252-4261. (Pubitemid 28287948)
41. Katzenellenbogen BS, Katzenellenbogen JA,. 2000. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2: 335-344. (Pubitemid 32223616)
42. Khan SA, Rogers MA, Obando JA, Tamsen A,. 1994. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 54: 993-997.
43. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang GH,. 2004. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 84: 479-484. (Pubitemid 41656475)
44. Kim HR, Oh BC, Choi JK, Bae SC,. 2008. Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem 105: 1048-1058.
45. Kim JH, Choi JK, Cinghu S, Jang JW, Lee YS, Li YH, Goh YM, Chi XZ, Lee KS, Wee H, Bae SC,. 2009. Jab1/CSN5 induces the cytoplasmic localization and degradation of RUNX3. J Cell Biochem 107: 557-565.
46. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S,. 2006. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520. (Pubitemid 44085605)
47. Lee YM,. 2011. Control of RUNX3 by histone methyltransferases. J Cell Biochem 112: 394-400.
48. Lee SH, Kim J, Kim WH, Lee YM,. 2009. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 28: 184-194.
49. Leung DC, Dong KB, Maksakova IA, Goyal P, Appanah R, Lee S, Tachibana M, Shinkai Y, Lehnertz B, Mager DL, Rossi F, Lorincz MC,. 2011. Lysine methyltransferase G9a is required for de novo DNA methylation and the establishment, but not the maintenance, of proviral silencing. Proc Natl Acad Sci USA 108: 5718-5723.
50. Levanon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, Eilam R, Bernstein Y, Goldenberg D, Xiao C, Fliegauf M, Kremer E, Otto F, Brenner O, Lev-Tov A, Groner Y,. 2002. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J 21: 3454-3463. (Pubitemid 34760577)
51. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y,. 2002. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124. (Pubitemid 34327521)
52. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA,. 2011. Epithelial-mesenchymal transition and cancer stem cells: A dangerously dynamic duo in breast cancer progression. Breast Cancer Res 13: 202.
53. Nigg EA,. 1997. Nucleocytoplasmic transport: Signals, mechanisms and regulation. Nature 386: 779-787. (Pubitemid 27181245)
54. Osborne C, Wilson P, Tripathy D,. 2004. Oncogenes and tumor suppressor genes in breast cancer: Potential diagnostic and therapeutic applications. Oncologist 9: 361-377. (Pubitemid 39014548)
55. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH,. 2011. Promoter CpG island hypermethylation during breast cancer progression. Virchows Archiv 458: 73-84.
56. Reya T, Clevers H,. 2005. Wnt signalling in stem cells and cancer. Nature 434: 843-850. (Pubitemid 40558990)
57. Shoker BS, Jarvis C, Clarke RB, Anderson E, Munro C, Davies MP, Sibson DR, Sloane JP,. 2000. Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 53: 778-783.
58. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL,. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874. (Pubitemid 32878711)
59. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC,. 2009a. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 113: 113-121.
60. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M,. 2009b. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796: 315-331.
61. Subramanian K, Jia D, Kapoor-Vazirani P, Powell DR, Collins RE, Sharma D, Peng J, Cheng X, Vertino PM,. 2008. Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell 30: 336-347. (Pubitemid 351615317)
62. Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Frenkel EP, Minna JD, Fujisawa T, Gazdar AF,. 2005. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 93: 1029-1037. (Pubitemid 41548398)
63. Tamaru H, Selker EU,. 2001. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414: 277-283. (Pubitemid 33097798)
64. Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, Ito Y,. 2007. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 18: 1225-1230.
65. Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y, Littman DR,. 2002. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111: 621-633. (Pubitemid 35441245)
66. Tateishi Y, Kawabe Y, Chiba T, Murata S, Ichikawa K, Murayama A, Tanaka K, Baba T, Kato S, Yanagisawa J,. 2004. Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 23: 4813-4823. (Pubitemid 40069711)
67. van der Vlag J, Otte AP,. 1999. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23: 474-478.
68. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM,. 2008. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699.
69. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F,. 2006. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874. (Pubitemid 43255707)
70. Weith A, Brodeur GM, Bruns GA, Matise TC, Mischke D, Nizetic D, Seldin MF, van Roy N, Vance J,. 1996. Report of the second international workshop on human chromosome 1 mapping 1995. Cytogenet Cell Genet 72: 114-144.
71. Widschwendter M, Jones PA,. 2002. DNA methylation and breast carcinogenesis. Oncogene 21: 5462-5482. (Pubitemid 34983482)
72. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M,. 2002. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: A tissue microarray study. Cancer Res 62: 497-505. (Pubitemid 34106424)
73. Yager JD, Davidson NE,. 2006. Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
74. Yamamura Y, Lee WL, Inoue K, Ida H, Ito Y,. 2006. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 281: 5267-5276. (Pubitemid 43847791)
75. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K, Ida H, Bouillet P, Strasser A, Bae SC, Ito Y,. 2006. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 26: 4474-4488. (Pubitemid 43877568)